What Cryoport does

Cryoport, Inc. (NASDAQ: CYRX), founded in 1999 and headquartered in Lake Forest, California, operates as an integrated temperature-controlled supply chain platform serving the life sciences industry. The company supports biopharmaceutical sponsors, contract research and manufacturing organizations (CROs/CDMOs), fertility clinics, and animal health customers with validated cryogenic (below -150°C), ultra-cold (-60 to -80°C), refrigerated (2-8°C), and controlled room temperature (15-25°C) logistics for biological materials including cell therapies, gene therapies, biologics, and reproductive materials. Cryoport supports 766 active clinical trials and 21 commercially approved cell and gene therapies globally, holding approximately 70% market share in the CGT clinical trial logistics sector.

The company's product portfolio spans proprietary shipping systems (Cryoport Express Cryogenic Standard/Combo/HV3, Cryomax, Elite Ultra Cold, C3), the Cryoport Safepak accessory system, the Cryoshuttle transportation service, IntegriCell cryopreservation services, BioServices (biostorage, kit production, secondary packaging, clinical sample management, regulatory/QP services), and consulting services. Technology infrastructure includes the Cryoportal logistics management platform (real-time shipment visibility and condition monitoring), the Veri-Clean proprietary decontamination process (eliminating 99.9999% of contaminants), the Chain of Compliance traceability system, and the Tec4med condition monitoring solution acquired in 2023. Cryoport operates from facilities in the US (New York, Los Angeles, Houston, and a planned Santa Ana center in Q4 2026), Europe (Paris, East Belgium, Germany), and serves over 150 countries for reproductive medicine logistics.

Cryoport generates revenue through four primary streams: Life Sciences Services (BioServices, IntegriCell, consulting; 56% of Q1 2026 revenue at $26.9M, 18% YoY growth), Product/Shipping Systems (proprietary containers and recurring rental/cycle fees; 44% at $20.9M, 15% YoY growth), Commercial Cell and Gene Therapy support ($9.1M, 26% YoY growth), and Transportation Services. The company employs a direct enterprise sales motion targeting biopharma sponsors through dedicated field sales teams, with distribution expanded via a strategic partnership with DHL Group established after the March 2025 divestiture of CRYOPDP for $195 million. FY2025 revenue reached $176.2 million, with FY2026 guidance raised to $192-196 million following Q1 2026 results.

Name

Cryoport

Legal name

Cryoport, Inc.

Website

https://cryoport.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

Cryoport, Inc. provides an integrated temperature-controlled logistics platform for life sciences, serving biopharma sponsors, CROs/CDMOs, fertility clinics, and animal health customers with proprietary cryogenic shipping systems, BioServices, and cryopreservation for cell and gene therapies.

Ownership category

akta.pro rank

Product category

Life Sciences Cold Chain Logistics

NAICS

Refrigerated Warehousing and Storage (493120), Ventilation, Heating, Air-Conditioning, and Commercial Refrigeration Equipment Manufacturing (33341)

SIC

Air-Cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip (3585)

akta.pro primary industry

Cryogenic Logistics (LN2 Dry Shippers, -150°C) (HLAGAMAB)

akta.pro secondary industries

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cryogenic / Ultra-Low Temperature Transport (e.g., dry ice, LN2) (TLADAHAJ), Dry Ice & Cryogenic (LN2) Handling and Transport Services (TLACAMAM)

Keywords

• Cryogenic logistics services
• Temperature-controlled shipping
• Biopharma cold chain
• Cell therapy logistics
• Life sciences transportation

Headquarters

HQ city

Lake Forest

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Life Sciences Services: Cryoport's largest revenue driver, including BioServices (biostorage, kit production, secondary packaging and labelling, clinical sample management, regulatory/QP services), cryopreservation services (IntegriCell), and consulting services. This segment grew 18% year-over-year in Q1 2026, generating $26.9 million.
2. Product Revenue (Shipping Systems): Revenue from the company's proprietary shipping systems including cryogenic, ultra-cold, and refrigerated containers, along with accessories. Grew 15% year-over-year in Q1 2026 to $20.9 million. Includes recurring rental/cycle fees for shipping containers.
3. Commercial Cell and Gene Therapy Revenue: Revenue specifically from supporting commercially approved cell and gene therapies, which grew 26% to $9.1 million in Q1 2026, driven by expansion in approved CGT programs. Supports 21 commercially approved CGTs as of Q1 2026.
4. Transportation/Logistics Services: Transportation services including Cryoshuttle for local deliveries and broader logistics for temperature-sensitive commodities at various temperatures. Note: CRYOPDP business was divested to DHL Group in 2025.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Cryoport provides end-to-end, outsourced temperature-controlled supply chain solutions for life sciences, encompassing proprietary cryogenic and ultra-cold shipping systems, transportation services (including Cryoshuttle), cryopreservation under the IntegriCell brand, BioServices (biostorage, kit production, secondary packaging, clinical sample management, regulatory/QP services), and consulting services for cell therapies, gene therapies, biologics, reproductive medicine, and animal health.

Product overview

Cryoport Systems offers a comprehensive, end-to-end temperature-controlled supply chain platform for the life sciences industry. The platform is architected as an integrated suite comprising: (1) Shipping Systems spanning multiple temperature ranges including cryogenic (below -150°C), ultra-cold (-60 to -80°C), refrigerated (2-8°C), and controlled room temperature (15-25°C) — featuring proprietary products such as Cryoport Express® Cryogenic Standard, Combo, and HV3 Shipping Systems, Cryomax®, Cryoport Elite® Ultra Cold, and Cryoport Express® C3™; (2) Transportation services including Cryoshuttle® for local logistics; (3) Cryopreservation services under the IntegriCell® brand for standardizing leukapheresis starting material workflows; (4) BioServices encompassing biostorage, kit production, secondary packaging and labelling, clinical sample management, and regulatory/QP services; (5) Technology platforms including Cryoportal® for logistics management, Veri-Clean® proprietary decontamination, Chain of Compliance® traceability, and the acquired Tec4med condition monitoring solution. The portfolio supports applications across cell therapy, gene therapy, biologics, animal health, and reproductive medicine.

Differentiator

Problem solved

Functional benefit

Brands

• IntegriCell: Cryopreservation services for advanced therapies, supporting consistent high-quality leukapheresis starting material
• Cryoportal
• Veri-Clean
• Chain of Compliance
• Cryoshuttle
• Cryoport Elite Ultra Cold
• MVE Fusion 800 Series

Products and services

• Cryoport Express Cryogenic Standard Shipping System Proprietary cryogenic shipping system designed to maintain temperatures below -150°C during transport of cell and gene therapies and other high-value biological materials.
• Cryoport Express Cryogenic Combo Shipping System Cryogenic shipping system for combined payload requirements at temperatures below -150°C, serving advanced therapy and biologics logistics.
• Cryoport Express Cryogenic HV3 Shipping System High-volume cryogenic shipping system engineered for larger payloads at temperatures below -150°C.
• Cryomax Cryogenic Shipping System Cryogenic shipping system designed for maximum payload capacity at temperatures below -150°C.
• Cryoport Elite Ultra Cold Shipping System Temperature-controlled shipping system designed for the -60°C to -80°C ultra-cold band for high-value sensitive shipments including gene therapies.
• Cryoport Express C3 Shipping System Shipping system for refrigerated (2-8°C) and controlled room temperature (15-25°C) commodities.
• Cryoport Safepak System Accessory packaging system used with Cryoport shipping containers to support safe transport of biological materials.
• Cryoshuttle Transportation Service Local cryogenic transportation service providing safe delivery of temperature-sensitive biological materials.
• IntegriCell Cryopreservation Cryopreservation service that standardizes protocols, processes, and equipment to support consistent, high-quality leukapheresis starting material for advanced therapy developers.
• BioServices & Biostorage Integrated BioServices offering covering biostorage, kit production, secondary packaging and labelling, clinical sample management, and regulatory/QP services for life sciences clients.
• Cryoportal Logistics Management Platform Logistics management platform providing real-time shipment visibility, continuous condition monitoring, and complete traceability throughout the temperature-controlled supply chain.
• Tec4med Condition Monitoring Digital condition monitoring solutions acquired from Tec4med Lifescience GmbH providing enhanced supply chain visibility for biopharmaceutical shipments.
• MVE Fusion 800 Series Self-sustaining cryogenic freezer providing high-capacity storage at temperatures at or below -150°C without continuous liquid nitrogen supply, for medical research, hospital pharmacies, and biorepositories.
• Consulting Services Supply chain consulting including shipping risk assessment, shipping lane qualification, packaging/shipping system performance qualification, and custom packaging and accessory development for life sciences clients.

Quantifiable outcome

• Over 1 million successful shipments completed
• +6 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered notable and core.

• Verismo TherapeuticsnotableStrategic or Co-development Partner · 25 June 2026Cryoport Systems' IntegriCell cryopreservation services were selected by Verismo Therapeutics to support clinical development of their SynKIR-110 and SynKIR-310 KIR-CAR T cell therapy programs currently in Phase 1 trials for solid tumors and B-cell malignancies. IntegriCell implements Verismo's proprietary cryopreservation process within its GMP-compliant quality management system.
• DHL GroupcoreStrategic or Co-development Partner · 31 March 2025Cryoport divested its CRYOPDP business to DHL Group for $195 million enterprise value, establishing a strategic partnership that leverages DHL's global logistics network across APAC and EMEA regions. The transaction strengthened Cryoport's financial position while maintaining partnership benefits for global distribution.
• Bluebird Express, LLCcoreStrategic or Co-development Partner · 16 November 2023Cryoport acquired Bluebird Express, a logistics provider specializing in domestic and international transportation services, to enhance its service offerings in the cell and gene therapy industry. The acquisition expands Cryoport's U.S. footprint leveraging Bluebird Express's key operational centers in New York and Los Angeles.
• Tec4med Lifescience GmbHnotableTechnology or Integration · 2 November 2023Cryoport acquired Tec4med Lifescience GmbH to expand its condition monitoring solutions and strengthen its European market presence. The acquisition aims to enhance Cryoport's digital supply chain offerings for the biopharmaceutical industry across the DACH region.
• Cell&Co BioServicesnotableStrategic or Co-development Partner · 18 April 2022Cryoport acquired Cell&Co BioServices, a French bioservices company, to expand its global supply chain network for life sciences, especially in regenerative medicine and cell therapies. The acquisition includes a strategic location in France and is expected to accelerate Cryoport's expansion timeline by approximately two years.
• F-AirgatenotableStrategic or Co-development Partner · 18 May 2021Cryoport expanded its global supply chain network through the acquisition of F-Airgate, a Belgium-based provider of temperature-controlled logistics. The acquisition enhances Cryoport's presence in Europe, particularly in the EU and EMEA regions, supporting growth of cell and gene therapies and clinical trials support, increasing capacity and local operational capabilities.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• World Courier (Cencora/AmerisourceBergen): World Courier is a global specialty logistics provider focused on temperature-controlled and time-sensitive transport for pharmaceuticals and life sciences, including cell and gene therapies. It is one of Cryoport's closest direct competitors in clinical trial and commercial biologistics.
• Marken (UPS Healthcare): Marken is UPS's life sciences logistics arm providing global clinical trial supply chain services, including direct-to-patient and cold-chain delivery. It directly competes with Cryoport in biopharma temperature-controlled logistics.
• Azenta Life Sciences (formerly Brooks Life Sciences): Azenta offers cold-chain sample storage, biorepository, and genomics services across the life sciences industry. It overlaps directly with Cryoport's BioServices and biostorage offerings.
• Biocair: Biocair is a specialist life sciences logistics provider focused on temperature-controlled and time-critical shipments for clinical trials and advanced therapies, directly comparable to Cryoport's shipping systems and transportation services.

Broad incumbents

• DHL Supply Chain / Life Sciences (DHL Group): DHL Group acquired Cryoport's CRYOPDP subsidiary and operates one of the world's largest cold-chain logistics networks. It is both a strategic partner to Cryoport and a broad incumbent competitor in life sciences transport.
• Thermo Fisher Scientific (Cold Chain & CDMO Services): Thermo Fisher offers an extensive suite of biopharma services including cold-chain logistics, biorepository, and CDMO capabilities, overlapping with Cryoport's BioServices and consulting offerings as a broad incumbent.
• FedEx Custom Critical: FedEx Custom Critical provides time- and temperature-sensitive freight services for life sciences and healthcare customers. It is a broader incumbent competitor in the temperature-controlled freight segment where Cryoport operates.

Emerging players

• BioLife Solutions: BioLife Solutions provides biopreservation tools, including cryopreservation media and storage products for cell and gene therapies. It is comparable to Cryoport's IntegriCell and cryopreservation services as a focused competitor in the CGT cold-chain ecosystem.
• CSafe Global: CSafe Global manufactures active and passive temperature-controlled shipping containers for the pharmaceutical industry. Its active container portfolio overlaps with Cryoport's Cryoport Elite and refrigerated/cold-chain shipping systems.
• Stirling Ultracold: Stirling Ultracold produces ultra-low temperature freezers used in life sciences storage and transport. It is comparable to Cryoport's MVE Fusion 800 Series and cryogenic storage equipment portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cryoport
• Xx.com/Cryoport
• Facebookfacebook.com/cryoport

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds13 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cryoport